3rd Induced Proximity-Based Drug Discovery Summit

Paid

Whilst still in infancy, the rise of multispecific drugs that drive induced proximity between otherwise disparate biological targets is shifting the drug discovery paradigm towards therapeutic interventions for previously undrugged, or hard-to-drug targets with clinical value. As the only industry dedicated forum to radically advance heterobifunct

25-27 July 2023

Healthcare

Proteomics-Driven Drug Discovery

Paid

While finding novel druggable targets and drug modalities for therapeutic intervention remains a top priority for the pharma/biotech industry, identifying and validating "good" targets and leads remains challenging. Cambridge Healthtech Institute’s conference on Proteomics-Driven Drug Discovery focuses on the use of mass spectrometry, biochemical,

26-27 September 2023

Healthcare

Antibodies Against Membrane Protein Targets – Part 1

Paid

As the industry increasingly shifts its attention to biologics, more attention is being paid to the prospect of developing biotherapeutics against membrane-bound targets. For these large target classes, biologics offer improved selectivity, an alternative for targets with known function that have not been amenable to small molecule drugs and the po

26-27 September 2023

Healthcare

Protein Degraders and Molecular Glues – Part 2

Paid

A new generation of molecules are being developed to disrupt protein-protein interactions and to hijack the cell’s natural machinery for targeted protein degradation. Proteolysis-targeting chimeras (PROTACs), molecular glues, and other modalities are utilizing the ubiquitin-proteasome, lysosome, and autophagy systems to seek out previously “undrugg

27-28 September 2023

Healthcare